2-Amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles with Microtubule-Disruptive, Centrosome-Declustering, and Antiangiogenic Effects in vitro and in vivo.
Antiangiogenic agents
Anticancer drugs
Centrosome de-clustering
Pyrano[3,2-c]chromene
Journal
ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013
Informations de publication
Date de publication:
18 05 2022
18 05 2022
Historique:
revised:
25
02
2022
received:
02
02
2022
pubmed:
1
3
2022
medline:
21
5
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
A series of fifteen 2-amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles (1 a-o) were synthesized via a three-component reaction of 4-hydroxycoumarin, malononitrile, and diversely substituted benzaldehydes or pyridine carbaldehydes. The compounds were tested for anticancer activities against a panel of eight human tumor cell lines. A few derivatives with high antiproliferative activities and different cancer cell specificity were identified and investigated for their modes of action. They led to microtubule disruption, centrosome de-clustering and G2/M cell cycle arrest in 518 A2 melanoma cells. They also showed anti-angiogenic effects in vitro and in vivo.
Identifiants
pubmed: 35226402
doi: 10.1002/cmdc.202200064
pmc: PMC9311119
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Benzopyrans
0
N-methylacetamide-oxotremorine M
3854-07-7
Oxotremorine
5RY0UWH1JL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202200064Informations de copyright
© 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH.
Références
Angew Chem Int Ed Engl. 2000 Sep 15;39(18):3168-3210
pubmed: 11028061
Eur J Med Chem. 2013 Oct;68:260-9
pubmed: 23988409
Dev Biol. 2002 Aug 15;248(2):307-18
pubmed: 12167406
Mol Oncol. 2011 Aug;5(4):324-35
pubmed: 21646054
Curr Drug Deliv. 2016;13(2):186-201
pubmed: 26135671
Anticancer Res. 2018 Jun;38(6):3393-3400
pubmed: 29848688
Cancer Res. 2007 Jul 1;67(13):6342-50
pubmed: 17616693
Trends Biochem Sci. 2005 Nov;30(11):630-41
pubmed: 16236519
Chem Biodivers. 2017 Mar;14(3):
pubmed: 27936296
Chem Sci. 2017 Mar 1;8(3):2107-2114
pubmed: 28348729
Oncotarget. 2013 Oct;4(10):1763-76
pubmed: 24091544
Clin Cancer Res. 2009 Apr 15;15(8):2594-601
pubmed: 19351751
J Surg Res. 2005 May 1;125(1):104-8
pubmed: 15836858
Br J Clin Pharmacol. 2017 Feb;83(2):255-268
pubmed: 27620987
Cancer Res. 2002 Apr 1;62(7):1935-8
pubmed: 11929805
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Cell Death Differ. 2012 Aug;19(8):1255-67
pubmed: 22653338
Sci Rep. 2016 Jun 24;6:28139
pubmed: 27338725
Curr Opin Cell Biol. 2012 Dec;24(6):809-15
pubmed: 23127609
Drug Resist Updat. 2006 Feb-Apr;9(1-2):74-86
pubmed: 16714139
Sci Transl Med. 2010 May 26;2(33):33ra38
pubmed: 20505215
J Med Chem. 2002 Apr 11;45(8):1697-711
pubmed: 11931625
Cell Death Dis. 2014 Nov 20;5:e1538
pubmed: 25412316
ChemMedChem. 2021 Apr 20;16(8):1199-1225
pubmed: 33591595
Int J Cancer. 1996 Sep 17;67(6):821-5
pubmed: 8824554
Arch Pharm (Weinheim). 2017 Sep;350(9):
pubmed: 28787092
Nat Protoc. 2010 Apr;5(4):628-35
pubmed: 20224563
Cancer Res. 2008 May 1;68(9):3269-76
pubmed: 18451153
Eur J Med Chem. 2008 Apr;43(4):694-706
pubmed: 17614164
Bioorg Med Chem Lett. 2005 Nov 1;15(21):4745-51
pubmed: 16143530
Int J Cancer. 2003 Mar 10;104(1):121-9
pubmed: 12532428
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
Nat Rev Cancer. 2005 Oct;5(10):773-85
pubmed: 16195750
Nature. 2004 Nov 18;432(7015):316-23
pubmed: 15549093
Anal Biochem. 2011 Oct 1;417(1):97-102
pubmed: 21704602
Cell Stem Cell. 2008 Feb 7;2(2):183-9
pubmed: 18371439
Drug Resist Updat. 2001 Oct;4(5):303-13
pubmed: 11991684
Cancer Res. 2016 Nov 15;76(22):6690-6700
pubmed: 27634760
Prog Cell Cycle Res. 2003;5:335-47
pubmed: 14593728
Genes Dev. 2008 Aug 15;22(16):2189-203
pubmed: 18662975
Curr Opin Cell Biol. 2008 Feb;20(1):53-63
pubmed: 18182282
Dev Biol. 2017 Oct 1;430(1):11-17
pubmed: 28760346
ChemMedChem. 2022 May 18;17(10):e202200064
pubmed: 35226402
Sci Rep. 2020 Jul 14;10(1):11568
pubmed: 32665552
Cell Prolif. 2003 Jun;36(3):131-49
pubmed: 12814430
Bioorg Chem. 2016 Aug;67:116-29
pubmed: 27372186
Nat Rev Drug Discov. 2010 Oct;9(10):790-803
pubmed: 20885410
Annu Rev Cell Dev Biol. 2000;16:89-111
pubmed: 11031231
Molecules. 2021 Mar 09;26(5):
pubmed: 33803309
Biochem Soc Trans. 2019 Oct 31;47(5):1209-1222
pubmed: 31506331
Drug Discov Today. 2002 Jan 15;7(2):143-7
pubmed: 11790626
Annu Rev Med. 1998;49:407-24
pubmed: 9509272
Biol Res. 2009;42(3):377-89
pubmed: 19915746
Mol Pharmacol. 1988 Aug;34(2):200-8
pubmed: 3412321
Cancer Res. 1998 Sep 1;58(17):3974-85
pubmed: 9731511
Chem Soc Rev. 2010 Apr;39(4):1233-9
pubmed: 20309483
J Neurosci. 2004 Apr 21;24(16):4070-81
pubmed: 15102922
Oncoscience. 2015 Feb 20;2(2):91-8
pubmed: 25859551
Biochem Biophys Res Commun. 2002 Dec 13;299(4):676-80
pubmed: 12459193
J Clin Oncol. 2006 Apr 10;24(11):1770-83
pubmed: 16603719
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Cancer J. 2015 Jul-Aug;21(4):267-73
pubmed: 26222078
RSC Adv. 2020 Nov 23;10(70):42644-42681
pubmed: 35514898
Sci Rep. 2018 Oct 25;8(1):15764
pubmed: 30361629
Eur J Med Chem. 2019 Feb 1;163:160-168
pubmed: 30503940
Oncogene. 2009 Aug 20;28(33):2925-39
pubmed: 19561645
Clin Cancer Res. 2005 May 1;11(9):3155-62
pubmed: 15867207
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
Assay Drug Dev Technol. 2009 Dec;7(6):560-72
pubmed: 20105026
Nature. 2007 Aug 16;448(7155):811-5
pubmed: 17700700